{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpModified=2015-02-12T17%3A52%3A06.427Z&max-date=2015-02-10&hansardHeading=Hereditary+Diseases", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-ddpModified=2015-02-12T17%3A52%3A06.427Z&max-date=2015-02-10&hansardHeading=Hereditary+Diseases", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpModified=2015-02-12T17%3A52%3A06.427Z&max-date=2015-02-10&_metadata=all&hansardHeading=Hereditary+Diseases", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-ddpModified=2015-02-12T17%3A52%3A06.427Z&max-date=2015-02-10&hansardHeading=Hereditary+Diseases", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpModified=2015-02-12T17%3A52%3A06.427Z&max-date=2015-02-10&hansardHeading=Hereditary+Diseases", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpModified=2015-02-12T17%3A52%3A06.427Z&max-date=2015-02-10&hansardHeading=Hereditary+Diseases", "items" : [{"_about" : "http://data.parliament.uk/resources/179004", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/179004/answer", "answerText" : {"_value" : "<p>The Human Fertilisation and Embryology Authority has advised that if Parliament passes the Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, it will need to design a regulatory process of which the consideration of \u201csignificant risk\u201d is a part. In designing that process it will take into account, where relevant, the existing regulatory process for embryo testing (preimplantation genetic diagnosis).<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2015-02-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-02-23T16:05:17.44Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-02-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Hereditary Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, with reference to Part 5 (a) (ii) of the Mitochndrial Donation Regulations 2015, how the Human Fertilisation and Embryology Authority plans to define a \"significant risk\" of having or developing serious mitochondrial disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1569", "label" : {"_value" : "Biography information for Robert Flello"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stoke-on-Trent South"}
      , "tablingMemberPrinted" : [{"_value" : "Robert Flello"}
      ], "uin" : "224080"}
    , {"_about" : "http://data.parliament.uk/resources/178544", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/178544/answer", "answerText" : {"_value" : "<p>The Government\u2019s analysis of estimated costs and benefits is contained in the Impact Assessment that was laid in Parliament, together with the Draft Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, on 17 December 2014.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The cost over 10 years was estimated at £11.1 million with the monetised benefit estimated at £329.2 million.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2015-02-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-02-12T17:20:11.13Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-02-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Hereditary Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the cost to the public purse of (a) treatments for mitochondrial disease involving mitochondrial donation and (b) treatments for mitochondrial disease that do not involve mitochondrial donation in each of the next five financial years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"}
      }
      , "tablingMemberConstituency" : {"_value" : "North Tyneside"}
      , "tablingMemberPrinted" : [{"_value" : "Mrs Mary Glindon"}
      ], "uin" : "223866"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}